EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 23-Jun-2026 10:16 ET (23-Jun-2026 14:16 GMT/UTC)

TAILORx and RxPONDER trials shift to a discovery platform for analyzing breast cancer recurrence using advanced tumor profiling and AI

ECOG-ACRIN Cancer Research Group
Business Announcement

One of the world's largest breast cancer tissue banks is being used to study how tumors evolve and identify markers that indicate the risk of cancer recurrence. The ECOG-ACRIN and SWOG research groups are collaborating with Caris Life Sciences to use advanced tumor profiling and artificial intelligence to analyze these samples and related information, aiming to better understand what drives an incurable late recurrence of breast cancer in other parts of the body years after the initial diagnosis.

Funder: U.S. Department of Defense

A "shell" is developed to protect the shape of gold nanoparticles

University of Córdoba
Peer-Reviewed Publication

A laboratory trial employs a molecule to stabilize gold nanoparticles, used in medical heat therapies to prolong their effectiveness

Journal: Advanced Functional Materials

“Pomegranate-like” lanthanide nanoprobes achieve record sensitivity for early cancer screening

Science China Press
Peer-Reviewed Publication

Dendritic mesoporous silica-lanthanide fluoride (DMS-CeF₃:Tb) nanocomposites with a pomegranate-like architecture have been fabricated through a facile in situ enrichment strategy. The strong single-particle luminescence and long photoluminescence lifetime of DMS-CeF₃:Tb nanoprobes enabled an ultrasensitive immunoassay for prostate specific antigen (PSA) with a detection limit of 41 fg mL^-1, which represents a 976-fold improvement over a commercial PSA enzyme-linked immunosorbent assay kit. Validation with PCa serum samples revealed a strong correlation with the hospital’s electrochemiluminescence immunoassay, confirming the clinical applicability of the nanoprobes. Additionally, targeted imaging and in vitro detection of cervical cancer cells were realized utilizing biotinylated DMS-CeF₃:Tb nanoprobes, enabling rapid cancer screening. These findings reveal the great potential of DMS-CeF₃:Tb as an efficient nano-bioprobe for early cancer diagnosis.

Journal: Science Bulletin

Common asthma drug shows promise against aggressive cancers

Northwestern University
Peer-Reviewed Publication

A drug widely used to treat asthma and allergies may also help fight aggressive cancers, reports a new Northwestern Medicine study that uncovered how tumors hijack common white blood cells to evade immunotherapy. The findings in mice and human tissues point to a practical, new way to improve treatment for tough tumors, such as triple-negative breast cancer, where immunotherapy often fails.

Journal: Nature Cancer

Alliance trial to study a targeted radiation approach after lung cancer surgery

Alliance for Clinical Trials in Oncology
Business Announcement

The Alliance for Clinical Trials in Oncology has a new clinical research study open to explore whether a more targeted form of radiation therapy lowers the chance of lung cancer returning after surgery. The study (Alliance A082402) is for people with non‑small cell lung cancer (NSCLC) who underwent chemotherapy and immunotherapy before surgery, but who still have cancer cells found in lymph nodes at the time of their operation. This is a situation many patients with lung cancer face.

Funder: Alliance for Clinical Trials in Oncology Foundation

Newly designed peptides suggest safer immunotherapies are within reach

Texas A&M University
Peer-Reviewed Publication

At the cellular level, one major calcium signaling pathway is known as store-operated calcium entry, or SOCE. In this pathway, the endoplasmic reticulum—a major intracellular calcium store—acts like a sensor-and-supply system. When calcium levels inside the endoplasmic reticulum fall, the protein stromal interaction molecule 1 (STIM1) detects the change and activates ORAI channels in the plasma membrane. ORAI1 forms the pore of the calcium release-activated calcium channel, or CRAC channel, allowing calcium from outside the cell to enter the cytosol and trigger downstream signaling.

Understanding how this pathway works—and how it can be controlled when it doesn’t—is the focus of research led by Yubin Zhou, director of the Center for Translational Cancer Research at the Texas A&M Health Institute of Biosciences and Technology and professor in the Texas A&M Naresh K. Vashisht College of Medicine.

Journal: Nature Communications
Funder: Blood Cancer United, Cancer Prevention and Research Institute of Texas

A revolutionary discovery in cancer treatment independent of organ origin

FLOGEN Star Outreach
Peer-Reviewed Publication

Davis Joseph was awarded the 2025 Ciechanover International Biology Award at the Sustainability through Science and Technology Summit 2025 (FLOGEN SIPS 2025) in Cebu, Philippines, for a breakthrough cancer discovery proposing organ-agnostic treatment strategies. His work identifies three universal cancer types based on dysfunctions in p14ARF/p53, DINO lncRNA, and MDM2 activity, and introduces a universal apoptosis network flowsheet built from the analysis of 174 scientific publications. The discovery supports a unified therapeutic framework for treating cancers regardless of the organ in which they originate and is presented as an example of Sustainable Medicine under the FLOGEN Sustainability Framework.

Journal: Cell Death Discovery
Funder: FLOGEN Technologies inc, TIMA Establishment
Meeting: Sustainability through Science and Technology 2025

Reversing T cell exhaustion improves effectiveness of myeloma immunotherapies

The Mount Sinai Hospital / Mount Sinai School of Medicine
Peer-Reviewed Publication

Researchers at the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb, and the University of Oxford have discovered a way to give worn-out immune cells a second wind in the fight against multiple myeloma. In two studies published this month in Blood, the Journal of the American Society of Hematology, (doi.org/10.1182/blood.2025030891 and 10.1182/blood.2025030873) they found that using the drug mezigdomide (a cereblon E3 ligase modulator developed by Bristol Myers Squibb) can help these cells regain their strength and better destroy cancer by restoring the immune system’s ability to attack cancer and significantly improving the effectiveness of next-generation immunotherapies.

Journal: Blood

Mizzou scientists discover a way to automate production of a cancer-fighting drug candidate

University of Missouri-Columbia
Peer-Reviewed Publication

Researchers at the University of Missouri, Cancer Targeted Technology (CTT) and Isotherapeutics Group (ITG) discovered an innovative method to speed production of a cancer-fighting drug candidate.

Journal: Nuclear Medicine and Biology
Funder: National Cancer Institute

Chemotherapy may influence the immune system in ways that affect tumor response, new study shows

Houston Methodist
Peer-Reviewed Publication

Chemotherapy can be life-saving for many patients, but not all tumors respond—and some that do, may eventually become resistant. Investigators at Houston Methodist have identified a possible explanation for this resistance, offering new insight into why certain cancers evade treatment.

Journal: Nature Communications

40
41
42
43
44